Journals / İstanbul Kanuni Sultan Süleyman Tıp Dergisi / 2018 / Cilt: 10 - Sayı: 3

Analysis of Emergency Service Admissions in Patients Who Were Using Oral Anticoagulants

Oral Antikoagülan Kullanan Hastaların Acil Servis Başvurularının İncelenmesi

Pages
132–137
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Among the participants, 28.2% (n=13) of the patients were male and 71.8% (n=33) of them were female with an overall mean age of 73.28±13.35 years.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Oral anticoagulants are used to be protected from thromboembolic diseases.
📊
Key Findings & Data:Material and Method: In the present study, a retrospective analysis was performed related to the reasons of referrals of the patients who used oral anticoagulants and indications of oral anticoagulants, electrocardiographic (ECG) findings, and period of drug use of the patients who applied to Emergency Department of Kanuni Sultan Suleyman Education and Research Hospital between July 2017 and January 2018 by scanning hospital information management system (HIMS) and patient files.
💡
Conclusion & Impact:Among the participants, 28.2% (n=13) of the patients were male and 71.8% (n=33) of them were female with an overall mean age of 73.28±13.35 years.
🔬Design:Review & Systematic Survey
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Oral anticoagulants are used to be protected from thromboembolic diseases. The present study was conducted to review the types of oral anticoagulants (OAC) used for the patients who are at risk of thromboembolic diseases with initiation of direct oral anticoagulants (DOACs) and emergency room admissions of these patients. Material and Method: In the present study, a retrospective analysis was performed related to the reasons of referrals of the patients who used oral anticoagulants and indications of oral anticoagulants, electrocardiographic (ECG) findings, and period of drug use of the patients who applied to Emergency Department of Kanuni Sultan Suleyman Education and Research Hospital between July 2017 and January 2018 by scanning hospital information management system (HIMS) and patient files. Results: Totally 46 patients on OAC were included into the study. Among the participants, 28.2% (n=13) of the patients were male and 71.8% (n=33) of them were female with an overall mean age of 73.28±13.35 years. The analysis of OAC types revealed use of warfarin by 39.1% (n=18), dabigatran by 23,9% (n=11), apixaban by 13,1% (n=6) and rivaroxaban by 23.9% (n=11) of the patients. There was not any statistically significant association between OAC type and cause of referral (p>0.05). The electrocardiographically detected cardiac rhythms were as normal sinus rhythm in 37.2% (n=16), atrial fibrillation (AF) in 55.8%, supraventricular tachycardia in 2.3% (n=1) and other rhythms (pace and bigeminy rhythm) in 4.7% (n=2 of the patients. Conclusion: We believe that increase in the number of studies conducted on use of DOACs, will further increase our knowledge on the safety and efficacy of these drugs, and indications for use of DOACs, therefore more comprehensive and multi-centered studies are needed.

Özet

Amaç: Oral antikoagülanlar tromboembolik hastalıklardan korunmak amacıyla kullanılmaktadır. Bu çalışma,direkt oral antikoagülanların (DOAK) kullanımının başlamasıyla tromboembolik hastalık riski taşıyan hastalardakullanılan oral antikoagülan (OAK) türleri ve acil başvurularını incelemek amacıyla yapılmıştır.Gereç ve Yöntem: Bu çalışmada, Kanuni Sultan SüleymanEğitim ve Araştırma Hastanesi Acil Tıp Kliniği’ne 01Temmuz 2017-01 Ocak 2018 tarihleri arasında başvuran veOAK kullanan hastaların başvuru nedenleri, kullanım endikasyonları, kullanım süreleri ve elektrokardiyografi (EKG)bulguları retrospektif olarak hastane bilgi yönetim sistemi(HBYS) ve hasta dosyaları incelenerek analiz edildi.Bulgular: OAK kullanan 46 hasta çalışmaya dâhil edildi.Hastaların %28,2 (n=13)’si erkek, %71,8 (n=33)’i kadınolup, yaş ortalaması 73,28±13,35 idi. Kullanılan OAK incelendiğinde, hastaların %39,1’inin (n=18) varfarin,%23,9’unun (n=11) dabigatran, %13,1’inin (n=6) apiksaban ve %23,9’unun (n=11) rivaroksaban kullandığı saptandı. Kullanılan OAK ile başvuru nedenleri arasında istatistiksel olarak anlamlı ilişki saptanmamıştır (p>0,05). HastalarınEKG’lerindeki ritimlere bakıldığında, %37,2’sinde (n=16)normal sinüs ritmi (NSR), %55,8’inde (n=24) atriyal fibirilasyon (AF), %2,3’ünde (n=1) supraventriküler taşikardi(SVT) ve %4,7’sinde (n=2) diğer (pace ve atrial bigemineritim) ritim şekilleri olduğu saptandı.Sonuç: DOAK’ların kullanımı ile ilgili yapılan çalışmalararttıkça bu ilaçların güvenilirliği ve etkinliği ile ilgili bilgimizin daha fazla artacağını ve DOAK’ların kullanım endikasyonlarında artış olabileceğini ve bu yüzden daha kapsamlı ve çok merkezli çalışmalara gereksinim olduğunudüşünmekteyiz

🔖

Cite This Article

DOĞAN, S., KALAFAT, U. M. (2022). Analysis of Emergency Service Admissions in Patients Who Were Using Oral Anticoagulants. İstanbul Kanuni Sultan Süleyman Tıp Dergisi, Cilt: 10 - Sayı: 3, 132–137. https://ajindex.com/articles/551047

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Humbert X, Roule V, Chequel M, et al. Non-vitamin K oral anticoagulant treatment in elderly patients with atrial fibrillation and coronary heart disease. Int J Cardiol. 2016;222:1079-83.
  2. Oldenburg J, Marinova M, Muller-Reible C, Watzka M. The vitamin K cycle. Vitam Horm. 2008;78:35-62.
  3. Poller L. International Normalized Ratios (INR): the first 20 years. J Thromb Haemost. 2004;2:849-60.
  4. De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol. 2012;59:1413-25.
  5. Vranckx P, Valgimigli M, Heidbuchel H. The significance of drug-drug and drug-food interactions of oral anticoagulation. Arrhythm Electrophysiol Rev. 2018;7(1):55-61.
  6. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):615-21.
  7. Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY. Comparative effectiveness and safety of nonvitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
  8. Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, ShahND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc.2016;5:e003725
  9. Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176:1662-71.
  10. Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2018; 7(8). pii:e008643.
  11. Lee SJ, Jang YJ, Cha EY, Kim HS, Lee SS, Shin JG. A haplotype of CYP2C9 associated with warfarin sensitivity i